[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"indocyanine-green-icg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:indocyanine-green-icg":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,60,92,122,145,172,211,238,273],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100604190","implementation-of-indocyanine-green-to-identify-sentinel-lymph-nodes-during-surgery-for-breast-cancer-100604190",false,"NCT07146295","Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer","Implementation of Fluorescence Imaging Using Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer","INFINITE","Inclusion Criteria:\n\n* Patients ≥ 18 years old.\n* DCIS or invasive breast cancer, confirmed by biopsy\n* Clinically node-negative, confirmed by preoperative axillary ultrasound\n* Indication for breast cancer surgery with SLN procedure via axillar incision\n\nExclusion Criteria:\n\n* Combined MARI procedure\n* Known allergy for Indocyanine Green (ICG), intravenous contrast or iodine\n* History of axillary lymph node dissection\n* Hyperthyroidism or thyroid cancer\n* Pregnancy or breast-feeding\n* No written informed consent according to ICH\u002FGCP and national regulations.","ALL","18 Years",{"count":20,"type":21},1760,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn how to successfully introduce a new method for finding the sentinel lymph node during breast cancer surgery into routine hospital care. The method uses a dye called indocyanine green (ICG) and a special camera to see the lymph node. The sentinel lymph node is the first lymph node that cancer is likely to spread to.\n\nIn the Netherlands, about 1 in 7 women develops breast cancer. Finding out whether cancer has spread to the lymph nodes is important for planning treatment and predicting outcomes. The current standard method for sentinel lymph node biopsy (SLNB) uses a radioactive tracer called radioisotope technetium-labeled (99mTc)-nanocolloid. While accurate, this method has several drawbacks: it exposes patients to radioactivity, requires an extra hospital visit or travel to another hospital due to limited nuclear medicine facilities, and is not sustainable. Surgeries using 99mTc can only take place on certain days due to logistical issues, and the signal from 99mTc can be disturbed by the tumor marker placed in the breast.\n\nICG works as well as 99mTc for SLNB and offers several advantages: it is given during surgery (no extra visit needed), produces no radiation, and reduces costs. However, it is still not widely used in the Netherlands because hospitals may not be familiar with it or unsure how to make the switch.\n\nThis study will introduce ICG step-by-step in several Dutch hospitals and evaluate how to make the change as smooth and effective as possible. It will take place in three stages: I) SLNB with 99mTc only (current practice); II) SLNB with both 99mTc and ICG (transition phase); III) SLNB with ICG only (full implementation).\n\nAll study procedures take place during planned surgery, with no extra hospital visits. After surgery, participants will receive a short questionnaire (10-15 minutes) to share their experiences with the procedure. Their feedback, combined with input from healthcare providers, will help researchers develop a uniform medical protocol, an implementation guide, and educational materials for surgeons and surgical trainees.\n\nThe aim is to make ICG widely available across the Netherlands, ensuring that care is less burdensome, more sustainable, and more cost-effective, while keeping treatment accessible in local hospitals.",[27,28,29,30,31,32,33,34,35],"Breast Cancer","Sentinel Lymph Node Biopsy (SLNB)","Sentinel Lymph Node Detection","Sentinel Lymph Node","Lymphatic Metastasis","Fluorescence Imaging","Indocyanine Green (ICG)","Radioisotopes","Lymph Node Mapping",[37,38,39,40,41,42,43,44,45,46],"Breast cancer","Sentinel lymph node biopsy","Lymphatic metastasis","Indocyanine green","Techetium nanocolloïd","Fluorescence imaging","Surgical oncology","Lymph node mapping","Implementation","Radioisotope","RECRUITING","2026-06-22",{"date":50,"type":51},"2026-06-25","ACTUAL",{"date":53,"type":51},"2025-04-18",{"date":55,"type":21},"2026-08",{"name":57,"class":58},"Isabelle Henskens","OTHER",7,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100643524","phase-4-comparing-intraoperative-indocyanine-green-fluorescence-imaging-with-standard-clinical-assessment-for-flap-perfusion-in-head-and-neck-reconstruction-vision-trial-100643524","NCT07635420","Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial)","Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction: A Randomised Controlled Trial (VISION Trial)","VISION","Inclusion Criteria:\n\n* Age ≥18 years at the time of inclusion\n* Scheduled to undergo microvascular free flap reconstruction as part of oncologic, trauma, or benign surgery in the head and neck area\n* Ability to understand study information and provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy to indocyanine green or iodine\n* Severe hepatic or renal impairment\n* Confirmed or suspected pregnancy\n* Breastfeeding",{"count":69,"type":21},244,[71],"PHASE4","This is a prospective multicentre randomised controlled trial evaluating whether intraoperative indocyanine green (ICG) fluorescence angiography improves outcomes in head and neck free flap reconstruction compared with standard clinical assessment of flap perfusion. Adult patients undergoing microvascular free flap reconstruction for oncologic, trauma, or benign head and neck defects will be randomised to either intraoperative ICG angiography or conventional clinical perfusion assessment. The primary outcome is partial flap loss requiring intervention within 30 days after surgery. Secondary outcomes include total flap loss, flap-related re-exploration, flap salvage, and postoperative complications.",[74,75,76,77,78,33,79,80],"Head and Neck Cancer (H&N)","Free Tissue Flaps","Free Flap","Free Flap Evaluation","Indocyanine Green","Microsurgery","Randomised Controlled Trial","NOT_YET_RECRUITING","2026-06-08",{"date":84,"type":51},"2026-06-09",{"date":86,"type":21},"2026-10-01",{"date":88,"type":21},"2029-08-01",{"name":90,"class":58},"Region Skane",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":99,"minAge":4,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":91},"100622213","the-effect-of-dose-and-storage-conditions-of-indocyanine-green-on-efficacy-and-cost-in-sentinel-lymph-node-mapping-in-gynecological-cancer-100622213","NCT07380698","The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological Cancer","DOSTCONICG","Inclusion Criteria:\n\n* cervical cancer, endometrial cancer, vulvar cancer, using indocyanine green, sentinel lymph node dissection\n\nExclusion Criteria:\n\n\\-","FEMALE",{"count":101,"type":21},30,"1 Month","OBSERVATIONAL","This research will determine the impact of optimizing dosage and storage conditions for indocyanine green on health outcomes and will contribute to improving treatment processes in gynecological cancers. Ultrastaging will increase the detection of micrometastases. Furthermore, the cost impact of these optimizations will be evaluated. It will help develop more effective, safe, and cost-effective methods for sentinel lymph node mapping in gynecological cancers. Furthermore, significant savings in healthcare costs could be achieved.",[106,107,108,33],"Endometrial Cancer","Vulvar Cancers","Cervical Cancer",[110,111,112],"endometrial cancer","vulvar cancers","cervical cancers","2026-01-23",{"date":115,"type":51},"2026-02-02",{"date":117,"type":51},"2025-10-03",{"date":119,"type":21},"2026-09-03",{"name":121,"class":58},"Cukurova University",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":99,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},"100620812","finding-sentinel-lymph-nodes-during-mastectomy-using-indocyanine-green-inigma-study-100620812","NCT07362485","Finding Sentinel Lymph Nodes During Mastectomy Using Indocyanine Green (INIGMA Study)","Indocyanine Green Guided Identification of Sentinel Lymph Nodes Via Mastectomy Incision in Breast Cancer Patients (INIGMA Study)","INIGMA","Inclusion Criteria:\n\n* Clinically node-negative, DCIS, invasive T1- T3 breast cancer confirmed by biopsy.\n* Preoperative axillary ultrasound to confirm clinical node-negative status.\n* Indication (or preference) for mastectomy and simultaneous SLN procedure.\n* Written informed consent according to ICH\u002FGCP and national regulations.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years old\n* Breast conserving surgery\n* Direct reconstruction (with autologous tissue or implant)\n* Known allergy for indocyanine green (ICG) or radioisotope technetium (99mTc), intravenous contrast or iodine\n* Other concurrent solid tumour\n* Hyperthyroidism or thyroid cancer\n* Pregnancy or breast feeding\n* Psychological, familial, sociological or geographical factors that could potentially hamper compliance with the study protocol",{"count":131,"type":21},90,[24],"This pilot study evaluates the diagnostic value of indocyanine green (ICG) fluorescence for sentinel lymph node biopsy (SLNB) performed through the mastectomy incision in breast cancer patients.\n\nWomen with clinically node-negative, invasive T1-T3 breast cancer undergoing mastectomy with SLNB at St. Antonius or Isala Hospital will be included. All patients receive standard 99mTc injection preoperatively, followed by 5 mg (2mL) ICG injection after anesthesia. The axilla will be explored for fluorescent lymph nodes via the mastectomy incision, avoiding a separate axillary incision.\n\nPrimary outcome: ICG detection rate for SLN identification via the mastectomy incision.\n\nSecondary outcomes: Comparison with 99mTc detection, number of nodes identified, concordance between methods, pathology differences, detection time, and complications.\n\nICG is safe, non-ionizing, and causes no extra discomfort or visits. Risks and burden are minimal.",[27,28,29,30,31,32,33,34,35,135],"Mastectomy",[37,38,40,135,42,44,43,41,46],"2026-01-15",{"date":113,"type":51},{"date":140,"type":51},"2022-08-22",{"date":142,"type":21},"2026-06",{"name":57,"class":58},2,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100612535","phase-1-a-prospective-single-centered-assessor-blinded-study-to-evaluate-the-clinical-efficacy-of-the-proposed-celltissue-histopathology-processor-ccell-confocal-fluorescence-endomicroscopy-for-intraoperative-diagnosis-in-brain-tumors-100612535","NCT07254845","A PROSPECTIVE, SINGLE-CENTERED, ASSESSOR-BLINDED STUDY TO EVALUATE THE CLINICAL EFFICACY OF THE PROPOSED CELL\u002FTISSUE HISTOPATHOLOGY PROCESSOR CCELL (CONFOCAL FLUORESCENCE ENDOMICROSCOPY) FOR INTRAOPERATIVE DIAGNOSIS IN BRAIN TUMORS","Inclusion Criteria:\n\n1. Male or female patients aged 18 years or older as of the screening date\n2. Patients suspected of having a brain tumor who are scheduled for neurosurgery and are considered candidates for tumor resection\n3. Patients who understand and have signed the informed consent form\n\nExclusion Criteria:\n\n1. Specimens obtained from patients who have agreed to participate in this clinical trial and who meet the inclusion criteria\n2. Normal tissue specimens obtained unavoidably during tumor resection surgery in tumor patients\n3. Tissue samples must be adequate for both FS and PS analysis\n4. Minimum lesion size of 1 cm for reliable cCeLL imaging",{"count":101,"type":21},[153],"PHASE1","The primary objective of this single-center study is to demonstrate the performance of cCeLL, used in real time, compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an aid in the visualization of vessels (micro- and macro-vasculature) blood flow in the cerebrovascular before, during or after cranial diagnostic and therapeutic procedures, such as tumor biopsy and resection, and the images will be immediately transmitted to a single pathologist for real-time evaluation, without influencing the surgical decision-making process. The comparison will be made between the device and the conventional intraoperative histological frozen section analysis of identical brain tissue samples in the same patient. Both methods will be compared in terms of their accuracy using the standard of practice, the final pathological diagnosis.",[156,33,157],"Frozen Sections","Brain Tumor",[159,160,161],"diagnostic imaging","intraoperative","confocal laser endomicroscopy","2025-11-19",{"date":164,"type":51},"2025-11-28",{"date":166,"type":21},"2025-12-01",{"date":168,"type":21},"2026-08-30",{"name":170,"class":171},"VPIX Medical","INDUSTRY",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":195,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":91},"100566245","sentinel-node-and-organ-sparing-surgery-in-stage-i-colon-carcinoma-100566245","NCT06652672","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma (SENTRY Trial)","SENTRY","Inclusion Criteria:\n\n* Oral and written informed consent (IC)\n* Aged 18 years and older\n* Fit for both organ-sparing surgery and colectomy\n* Pathologically confirmed T1-2 adenocarcinoma of the colon following R0, R1, or Rx endoscopic resection with an estimated LNM risk \\>15% (Table 5.2.2. in module 5.2 of the Dutch CRC guideline); or a lesion macroscopically suspected to be (deep-invasive) T1 colon cancer, measuring \\\u003C40 mm, for which wedge resection is considered the most suitable local resection technique as recommended by the MDT\n* The resection scar after local excision is expected to be clearly recognized at endoscopy, either by a tattoo or by detecting a scar in the colorectal segment where no other polypectomies were performed\n* Lesion located \\>25cm from the anus based on endoscopic measurement, or above sigmoid take-off\n\nExclusion Criteria:\n\n* Patients who opt for active follow-up instead of surgery following shared decision-making\n* Distant metastasis\n* Lynch syndrome\n* Another active malignancy requiring palliative treatment at the time of colon cancer diagnosis\n* Previous colorectal cancer within the last 5 years\n* Tumours that comprised \\>50% of the colon circumference before resection\n* Tumours involving the ileocaecal valve\n* Pregnancy, lactation or a planned pregnancy during the course of the study\n* Known allergy to any of the compounds used for SLN identification (ICG, Iodine or Sodium iodide)\n* Previous colonic surgery (excluding appendectomy)\n* Contra-indication for laparoscopic or robotic surgery\n* Severe kidney- or liver failure\n* Hyperthyroidism or an autonomously functioning thyroid adenoma",{"count":181,"type":21},341,[24],"The aim of this study is to reduce the need for colectomy and its' associated morbidity and mortality in patients with pT1-2 colon carcinoma after endoscopic resection and an estimated lymph node metastasis (LNM) risk of \\>15%, or with macroscopically suspected T1 tumors, by performing an endoscopic-assisted laparoscopic\u002Frobotic wedge resection of the tumor or scar, along with sentinel node (SLN) biopsy using indocyanine green (ICG). This intervention will be compared to the standard-of-care segmental resection using a partially randomized patient preference design. The primary outcome is the 3-year recurrence rate.",[185,186,30,187,188,189,190,191,192,193,194,33],"Colon Cancer","Colon Adenocarcinoma","Sentinel Lymph Node Biopsy","Colon Neoplasms","Colon Neoplasm","Fluorescence","Fluorescence Guided Surgery","Fluorescence Laparoscopy","Fluorescence-guided Resection","Colon Surgery",[196,190,197,198,199,200,201],"Colon cancer","Sentinel lymph node","Indocyanine green (ICG)","Organ sparing surgery","Organ preserving surgery","Local resection","2025-11-17",{"date":204,"type":51},"2025-11-20",{"date":206,"type":51},"2024-12-12",{"date":208,"type":21},"2032-12-12",{"name":210,"class":58},"Meander Medical Center",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":220,"studyType":103,"phases":4,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":91},"100606862","the-use-of-indocyanine-green-fluorescence-icg-during-laparoscopic-heller--dor-100606862","NCT07181070","The Use of Indocyanine Green Fluorescence (ICG) During Laparoscopic Heller- Dor","The Use of Indocyanine Green Fluorescence (ICG) During Laparoscopic Heller- Dor: a Prospective Study","Inclusion Criteria:\n\n* patients with achalasia of type I and II\n* patients undergoing laparoscopic Heller-Dor\n* patients older than 18 years\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age;\n* Uncooperative patients and\u002For patients unable to provide informed consent\n* ASA ≥4\n* BMI ≥30\n* Patients previously treated with other endoscopic\u002Fsurgical procedures (botulinum toxin injections, dilation, POEM, myotomy)\n* Patients with achalasia type III\n* Patients with megaesophagus\n* Allergy to dyes or contrast agents included in the protocol (e.g., indocyanine green, barium, gastrografin)",{"count":219,"type":21},70,"1 Year","The aim this prospective observational study is to evaluate the role of Indocyanine Green Fluorescence (ICG) in patients with achalasia underwent to Heller-Dor laparoscopic. The main gol are:\n\n* If with use of ICG iatrogenic mucosal leaks can be identified and, if necessary, improve the myotomy.\n* Assess the need for postoperative radiographic control using esophagogastric radiography with gastrografin.\n* Compare clinical characteristics, perioperative outcomes, and 12-month postoperative follow-up between the two populations.",[223,224,33,78],"Achalasia, Esophageal","Achalasia",[226,227,228],"achalasia","Laparoscopic Heller-Dor","Indocyanine Green Fluorescence","2025-09-18",{"date":231,"type":51},"2025-09-23",{"date":233,"type":51},"2022-11-01",{"date":235,"type":21},"2026-10-31",{"name":237,"class":58},"Federico II University",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":99,"minAge":18,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":22,"phases":247,"briefSummary":248,"conditions":249,"keywords":258,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":91},"100604083","phase-4-assessing-the-efficacy-of-indocyanine-green-for-ureter-identification-during-robot-assisted-surgery-in-advanced-stage-endometriosis-100604083","NCT07144904","Assessing the Efficacy of Indocyanine Green for Ureter Identification During Robot-Assisted Surgery in Advanced-Stage Endometriosis","A Side-Randomized, Self-Controlled Trial Assessing the Efficacy of Indocyanine Green Fluorescence Imaging for Intraoperative Ureter Identification During Robot-Assisted Single-Site Surgery in Advanced-Stage Endometriosis","Inclusion Criteria:\n\n* Stage III or IV endometriosis (rASRM classification)\n* Planned robotic transabdominal endometriosis excision with or without hysterectomy.\n\nExclusion Criteria:\n\n\\- Subjects who are part of a vulnerable population will be excluded including those who are prisoners, younger than 18 years old, pregnant, individuals with mental disabilities or cognitive impairment.",{"count":246,"type":21},40,[71],"The goal of this side-randomized, self-controlled trial, 1-site study is to explore the efficacy of Indocyanine Green Fluorescence (ICG) for Intraoperative Ureter Identification During Robot-Assisted Single-Site Surgery in Advanced-Stage Endometriosis.\n\nResearchers will perform temporary ureteral stent using indocyanine green fluorescence for intraoperative ureteral identification on either the left or right side of subjects who are undergoing a robotic assisted transumbilical resection of advanced endometriosis.\n\nParticipants will be randomized to receive ICG-assisted ureteral identification on either the left or right side. Randomization will be conducted using a computer-generated block randomization method.\n\nThe primary aim is to determine whether ICG-assisted ureter visualization can reduce operative time for endometriosis resection and ureterolysis, and minimize the risk of ureteral injury.\n\nSecondary objectives are to assess the feasibility and safety of temporary ureteral ICG stenting for intraoperative ureter identification in advanced endometriosis.",[33,250,251,252,253,254,255,256,257],"Robotic Surgical Procedure","Deep Infiltrating Endometriosis (DIE)","Endometriosis Pelvic","Endometriosis (Diagnosis)","Endometriosis of the Cul-de-sac","Ureteral Stent Placement","Ureteral Injury","Endometriosis Ovaries",[259,260,261,262,263],"ureteral stent placement","indocyanine green","endometriosis","robotic surgery","ureteral identification","2025-08-20",{"date":266,"type":51},"2025-08-28",{"date":268,"type":21},"2025-10-01",{"date":270,"type":21},"2026-03-15",{"name":272,"class":58},"Baylor College of Medicine",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":291,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":91},"100584672","application-of-indocyanine-green-tracer-in-d2-lymphadenectomy-of-locally-advanced-gastric-cancer-100584672","NCT06892392","Application of Indocyanine Green Tracer in D2 Lymphadenectomy of Locally Advanced Gastric Cancer","Aplicación Del ICG En La Linfadenectomía D2 Laparoscópica Del Cáncer Gástrico Localmente Avanzado: Ensayo Clínico Aleatorizado Multicéntrico.","Gastri-ICG","Inclusion Criteria:\n\n* T2-T4a, N+, M0 on preoperative study\n* PS 0-1\n* ASA I-III\n* Laparoscopic surgery\n\nExclusion Criteria:\n\n* \\- Previous gastric abdominal surgery\n* DSE\n* Cognitive impairment\n* Allergic to iodine\n* Synchronous neoplasm\n* Stroke in the last 6 months\n* Angina or AMI in the last 6 months\n* Plastic lymphitis\n* Open surgery","85 Years",{"count":283,"type":21},102,[24],"Gastric cancer is a frequent neoplasm in the world, presenting more than one million new cases and around 768,000 deaths in the data registered in 2020. Among the therapeutic options for gastric cancer, surgery is an essential pillar for its treatment. Gastric cancer surgery consists of gastric resection with negative margins and radical lymphadenectomy in patients without distant metastases. It has been demonstrated over the years that radical lymphadenectomy in gastric cancer allows for adequate staging and improved long-term survival.\n\nIn order to perform a correct staging using the TNM system, it is necessary to resect at least 15 lymph nodes in the radical lymphadenectomy. For radical lymphadenectomy staging, the Japanese Gastric Cancer Association defined and subdivided nodal stations. Three types of lymphadenectomy are described according to oncologic gastric resections (D1, D1+ and D2), with D2 lymphadenectomy being the standard of treatment for locally advanced gastric tumors. Performing an insufficient or inadequate lymphadenectomy has been shown to negatively impact survival after gastrectomy in such a cohort.\n\nThe development of technology based on fluorescence guided by indocyanine green could improve the technique and results of D2 lymphadenectomy in patients with gastric cancer. There is evidence that the application of ICG in D2 lymphadenectomy increases the number of resected nodes, however, studies of higher scientific quality (randomized clinical trials) are needed. Furthermore, most studies in this field have focused on Eastern countries (Japan, Korea and China), where the percentage of early tumors and chemotherapy treatment is different from Western centers.\n\nTherefore, we propose a multicenter randomized clinical trial aimed at evaluating whether the application of ICG-guided fluorescence-based technology in D2 lymphadenectomy of locally advanced gastric cancer increases the number of resected nodes, improves the oncologic quality of the lymphadenectomy, and thus may increase overall survival and disease-free survival at 2 and 5 years postoperatively.",[287,33,288,289,290],"GASTRIC CANCER","Lymph Node Excision","Lymphadenectomy","Laparoscopic Gastrectomy",[292,260,293],"Multicenter randomized 1:1 clinical trial","Laparoscopic gastrectomy with D2 lymphadenectomy","2025-03-18",{"date":296,"type":51},"2025-03-24",{"date":298,"type":21},"2026-03-01",{"date":300,"type":21},"2032-12",{"name":302,"class":58},"Hospital of Navarra"]